FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer

AIM Currently, the German and Austrian S3 guidelines on the evaluation and treatment of lung cancer are about to be published whereas the American Colleague of Chest Physicians (ACCP) guidelines were already presented in 2007. An important part of the diagnostic workup of lung cancer will be the evaluation of indeterminate lung lesions and the mediastinal and extrathoracic staging using FDG-PET or PET/CT. The results from the literature on FDG-PET and PET/CT as well as on conventional nuclear medicine staging procedures and the clinical implications are presented. METHODS The literature data was amassed in analogy to the meta-analyses drawn for the current ACCP guidelines. In addition, relevant more recent publications were also considered. To answer the important question for the extent of pathological confirmation needed, the residual risk of mediastinal metastases was calculated for certain constellations of FDG-PET and CT findings. Suggested recommendations were characterized with the level of evidence. RESULTS FDG-PET (PET/CT) allows the differentiation of indeterminate lung lesions with high accuracy. FDG-PET (PET/CT) is the most accurate non-invasive procedure to assess the mediastinal nodal stage, for non-small cell as well as for small cell lung cancer. It is justified to omit invasive evaluation of enlarged but FDG-PET negative lymph nodes under certain circumstances. Unexpected extrathoracic metastases detected by FDG-PET imply important changes in therapeutic management. CONCLUSION The upcoming S3 guideline on lung cancer will recommend FDG-PET in several indications due to its clinical efficacy well proven by data from literature (high level of evidence). The selected use of conventional nuclear medicine procedures remains beyond doubt. FDG-PET (PET/CT) belongs to the standard of care in lung cancer.

[1]  C. Pugliese,et al.  Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy. , 1998, Lung cancer.

[2]  P C Goodman,et al.  Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.

[3]  Richard P Baum,et al.  Imaging of neuroendocrine tumors. , 2006, Seminars in nuclear medicine.

[4]  M. J. Fusselman,et al.  Brain metastases from non-central nervous system tumors: evaluation with PET. , 1993, Radiology.

[5]  Ora Israel,et al.  Cancer Recurrence: Diagnostic Value and Impact on Patient Management , 2004 .

[6]  N. Willich,et al.  [FDG-PET/CT in oncology. German Guideline]. , 2007, Nuklearmedizin. Nuclear medicine.

[7]  A. Hogg,et al.  High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[8]  Michael E Phelps,et al.  Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. , 2005, Chest.

[9]  G. Sybrecht,et al.  Diagnostische Aussagekraft der Positronen-Emissions-Tomographie (PET) bei zerebralen Metastasen von Bronchialkarzinomen , 1999, Medizinische Klinik.

[10]  Eric Turcotte,et al.  Application of a neural network to improve nodal staging accuracy with 18F-FDG PET in non-small cell lung cancer. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  M. Gould,et al.  A Clinical Prediction Rule to Estimate the Probability of Mediastinal Metastasis in Patients with Non-small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  M. Boers,et al.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.

[13]  Douglas K Owens,et al.  Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. , 2003, Annals of internal medicine.

[14]  T. Stijnen,et al.  Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. , 2005, The Annals of thoracic surgery.

[15]  Ursula Nestle,et al.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  T. Naruke,et al.  Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. , 2004, Lung cancer.

[17]  M. King,et al.  Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Hörsch,et al.  Receptor PET/CT imaging of neuroendocrine tumors. , 2008, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[19]  J. Mortensen,et al.  Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. , 2001, The Lancet. Oncology.

[20]  S. Zwas,et al.  Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. , 2005, The Israel Medical Association journal : IMAJ.

[21]  W Michael Alberts,et al.  Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). , 2007, Chest.

[22]  C. Dooms,et al.  Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. , 2004, The Lancet. Oncology.

[23]  U. Nestle,et al.  FDG-PET-based radiotherapy planning in lung cancer: optimum breathing protocol and patient positioning--an intraindividual comparison. , 2009, International journal of radiation oncology, biology, physics.

[24]  M. Wahidi,et al.  Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[25]  M. Dietlein,et al.  PET mit 18 F-Fluordeoxyglukose in der Diagnostik des nicht kleinzelligen Bronchialkarzinoms: evidenzbasierte Empfehlungen und Kosten/Nutzenabwägungen , 2003 .

[26]  K. Rosenzweig,et al.  Probability of mediastinal involvement in non-small-cell lung cancer: a statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy? , 2006, International journal of radiation oncology, biology, physics.

[27]  E. Stoelben,et al.  Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  D. Hellwig,et al.  Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[29]  Ursula Nestle,et al.  Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  Hironobu Ohmatsu,et al.  Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer , 2007 .

[31]  William Spies,et al.  Staging and Monitoring of Small Cell Lung Cancer Using [18F]Fluoro-2-deoxy-D-glucose-Positron Emission Tomography (FDG-PET) , 2007, American journal of clinical oncology.

[32]  M. Bamberg,et al.  Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren1 - Diskussionsbasis der deutschen Konsensus-Konferenz Onko-PET 2000 - , 2001 .

[33]  R. Baum,et al.  Stellenwert der PET bzw. PET/CT mit F-18-FDG beim kleinzelligen Lungenkarzinom , 2008, Der Onkologe.

[34]  Alfred A Bartolucci,et al.  The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. , 2004, The Annals of thoracic surgery.

[35]  H. Hansen,et al.  A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[37]  S. Swensen,et al.  Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection--pilot study. , 1999, Radiology.

[38]  Y. Ung,et al.  18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. , 2007, Journal of the National Cancer Institute.

[39]  Michael K Gould,et al.  Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). , 2007, Chest.

[40]  D K Owens,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[41]  S. Mayor.  NICE issues guidance for diagnosis and treatment of lung cancer , 2005, BMJ : British Medical Journal.

[42]  Douglas C McCrory,et al.  Noninvasive staging of non-small cell lung cancer: a review of the current evidence. , 2003, Chest.

[43]  B. Skogseid,et al.  Octreoscan in patients with bronchial carcinoid tumours , 2003, Clinical endocrinology.

[44]  Michael Wallace,et al.  Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[45]  H. Groen,et al.  Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  D. Hellwig,et al.  18F-FDG PET for Mediastinal Staging of Lung Cancer: Which SUV Threshold Makes Sense? , 2007, Journal of Nuclear Medicine.